The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis

PURPOSE: To systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-L1 antibodies for treatment of patients with advanced or refractory cancer. RESULTS: Fifty-one trials including 6,800 patients were included. The overall response rates for melanoma, non-small cell lung cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tengfei, Xie, Jing, Arai, Seiji, Wang, Liping, Shi, Xuezhong, Shi, Ni, Ma, Fen, Chen, Sen, Huang, Lan, Yang, Li, Ma, Wang, Zhang, Bin, Han, Weidong, Xia, Jianchuan, Chen, Hu, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341964/
https://www.ncbi.nlm.nih.gov/pubmed/27683031
http://dx.doi.org/10.18632/oncotarget.12230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341964/
https://www.ncbi.nlm.nih.gov/pubmed/27683031
http://dx.doi.org/10.18632/oncotarget.12230

Ejemplares similares